| Lymphoma, Follicular

Yescarta vs Zevalin

Side-by-side clinical, coverage, and cost comparison for lymphoma, follicular.

Deep comparison between: Yescarta vs Zevalin with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsZevalin has a higher rate of injection site reactions vs Yescarta based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Zevalin but not Yescarta, including UnitedHealthcare

Category

Yescarta

Zevalin

At A Glance

RouteIV infusion

FrequencySingle infusion

ClassCD19-directed CAR T cell immunotherapy

RouteIV infusion

FrequencySingle course

ClassCD20-directed radioimmunotherapy

Indications

Diffuse Large B-Cell Lymphoma
Mediastinal (Thymic) Large B-Cell Lymphoma
High grade B-cell lymphoma
Lymphoma, Follicular

Lymphoma, Follicular

Dosing

Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, High grade B-cell lymphoma Target dose 2 x 10^6 CAR-positive viable T cells per kg body weight (max 2 x 10^8 cells) as a single IV infusion; pretreat with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on days -5, -4, and -3 before infusion.

Lymphoma, Follicular Target dose 2 x 10^6 CAR-positive viable T cells per kg body weight (max 2 x 10^8 cells) as a single IV infusion; pretreat with cyclophosphamide 500 mg/m2 IV and fludarabine 30 mg/m2 IV on days -5, -4, and -3 before infusion.

Lymphoma, Follicular Day 1: rituximab 250 mg/m2 IV; Day 7, 8, or 9: rituximab 250 mg/m2 IV then Y-90 Zevalin 0.4 mCi/kg IV over 10 minutes (platelets >=150,000/mm3) or 0.3 mCi/kg IV over 10 minutes (platelets 100,000-149,000/mm3, relapsed or refractory); maximum dose 32 mCi; single course.

Contraindications

—

Drug Interactions

26View drug interactions

435View drug interactions

Adverse Reactions

Most common (>=30%) CRS, fever, hypotension, encephalopathy, fatigue, tachycardia, headache, nausea, febrile neutropenia, diarrhea, musculoskeletal pain, infections with pathogen unspecified, chills, decreased appetite

Serious CRS, fever, encephalopathy, hypotension, infection with unspecified pathogen, pneumonia, febrile neutropenia, cardiac arrhythmia, cardiac failure, aphasia, hypoxia

Postmarketing Spinal cord edema, myelitis, quadriplegia, dysphagia, status epilepticus, infusion related reactions, T cell malignancies

Most common (>=5%) Cytopenias (thrombocytopenia, neutropenia, anemia, leukopenia, lymphopenia), fatigue, nasopharyngitis, nausea, abdominal pain, asthenia, cough, diarrhea, pyrexia

Serious Prolonged and severe cytopenias (thrombocytopenia, anemia, lymphopenia, neutropenia), MDS/AML, serious infusion reactions, severe cutaneous and mucocutaneous reactions

Postmarketing Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous dermatitis, exfoliative dermatitis, infusion site erythema and ulceration, radiation injury

Pharmacology

CD19-directed genetically modified autologous T cell immunotherapy; upon engagement with CD19-expressing target cells, the CD28 and CD3-zeta co-stimulatory domains activate downstream signaling cascades leading to T cell activation, proliferation, and killing of CD19-expressing cancer cells and normal B cells.

Ibritumomab tiuxetan is a murine IgG1 kappa monoclonal antibody immunoconjugate that binds specifically to the CD20 antigen on pre-B and mature B lymphocytes and >90% of B-cell NHL; the covalently linked Y-90 chelate (tiuxetan) delivers targeted beta radiation, inducing cellular damage via free radical formation in CD20-expressing and neighboring cells.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Yescarta